Literature DB >> 28975588

Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure.

Anett H Ottesen1,2,3, Geir Christensen2,3, Torbjørn Omland1,2, Helge Røsjø4,5,6.   

Abstract

PURPOSE OF REVIEW: Endocrine and paracrine factors influence the cardiovascular system and the heart by a number of different mechanisms. The chromogranin-secretogranin (granin) proteins seem to represent a new family of proteins that exerts both direct and indirect effects on cardiac and vascular functions. The granin proteins are produced in multiple tissues, including cardiac cells, and circulating granin protein concentrations provide incremental prognostic information to established risk indices in patients with myocardial dysfunction. In this review, we provide recent data for the granin proteins in relation with cardiovascular disease, and with a special focus on chromogranin A and heart failure. RECENT
FINDINGS: Chromogranin A is the most studied member of the granin protein family, and shorter, functionally active peptide fragments of chromogranin A exert protective effects on myocardial cell death, ischemia-reperfusion injury, and cardiomyocyte Ca2+ handling. Granin peptides have also been found to induce angiogenesis and vasculogenesis. Protein glycosylation is an important post-translational regulatory mechanism, and we recently found chromogranin A molecules to be hyperglycosylated in the failing myocardium. Chromogranin A hyperglycosylation impaired processing of full-length chromogranin A molecules into physiologically active chromogranin A peptides, and patients with acute heart failure and low rate of chromogranin A processing had increased mortality compared to other acute heart failure patients. Other studies have also demonstrated that circulating granin protein concentrations increase in parallel with heart failure disease stage. The granin protein family seems to influence heart failure pathophysiology, and chromogranin A hyperglycosylation could directly be implicated in heart failure disease progression.

Entities:  

Keywords:  Cardiovascular disease; Chromogranin A; Glycosylation; Heart failure; Secretoneurin

Mesh:

Substances:

Year:  2017        PMID: 28975588     DOI: 10.1007/s11897-017-0360-x

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  92 in total

1.  Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction.

Authors:  Mette Elise Estensen; Aina Hognestad; Unni Syversen; Iain Squire; Leong Ng; John Kjekshus; Kenneth Dickstein; Torbjørn Omland
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

2.  Chromofungin, CgA47-66-derived peptide, produces basal cardiac effects and postconditioning cardioprotective action during ischemia/reperfusion injury.

Authors:  Elisabetta Filice; Teresa Pasqua; Anna Maria Quintieri; Patrizia Cantafio; Francesco Scavello; Nicola Amodio; Maria Carmela Cerra; Céline Marban; Francis Schneider; Marie-Hélène Metz-Boutigue; Tommaso Angelone
Journal:  Peptides       Date:  2015-07-04       Impact factor: 3.750

3.  The antihypertensive chromogranin a peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism.

Authors:  Tommaso Angelone; Anna Maria Quintieri; Bhawanjit K Brar; Pauline T Limchaiyawat; Bruno Tota; Sushil K Mahata; Maria Carmela Cerra
Journal:  Endocrinology       Date:  2008-06-05       Impact factor: 4.736

4.  Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum.

Authors:  D T O'Connor
Journal:  Regul Pept       Date:  1983-07

Review 5.  Chromogranin-A: a multifaceted cardiovascular role in health and disease.

Authors:  T Angelone; R Mazza; M C Cerra
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  Prognostic Value of Secretoneurin in Patients with Acute Respiratory Failure: Data from the FINNALI Study.

Authors:  Peder L Myhre; Anett H Ottesen; Marjatta Okkonen; Rita Linko; Mats Stridsberg; Ståle Nygård; Geir Christensen; Ville Pettilä; Torbjørn Omland; Helge Røsjø
Journal:  Clin Chem       Date:  2016-08-18       Impact factor: 8.327

7.  Effect of short- and long-term physical activities on circulating granin protein levels.

Authors:  Helge Røsjø; Per-Kristian Opstad; Jon Erik Hoff; Kristin Godang; Geir Christensen; Mats Stridsberg; Torbjørn Omland
Journal:  Regul Pept       Date:  2013-06-28

8.  Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.

Authors:  Sandra Cappello; Tommaso Angelone; Bruno Tota; Pasquale Pagliaro; Claudia Penna; Raffaella Rastaldo; Angelo Corti; Gianni Losano; Maria Carmela Cerra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-06       Impact factor: 4.733

Review 9.  In search of new therapeutic targets and strategies for heart failure: recent advances in basic science.

Authors:  Ajay M Shah; Douglas L Mann
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

Review 10.  The chromogranins A and B: the first 25 years and future perspectives.

Authors:  H Winkler; R Fischer-Colbrie
Journal:  Neuroscience       Date:  1992-08       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.